Avantor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 27, 2023 at 06:05 am EDT
Share
Avantor, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 1,720.2 million compared to USD 1,856.5 million a year ago. Net income was USD 108.4 million compared to USD 167 million a year ago. Basic earnings per share from continuing operations was USD 0.16 compared to USD 0.25 a year ago. Diluted earnings per share from continuing operations was USD 0.16 compared to USD 0.25 a year ago.
For the nine months, sales was USD 5,244.4 million compared to USD 5,717.4 million a year ago. Net income was USD 222.6 million compared to USD 544.8 million a year ago. Basic earnings per share from continuing operations was USD 0.33 compared to USD 0.81 a year ago. Diluted earnings per share from continuing operations was USD 0.33 compared to USD 0.8 a year ago.
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies & applied materials industries. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
AVANTOR, INC. 
